Assessment of AXL and mTOR genes expression in medullary thyroid carcinoma (MTC) cell line in relation with over expression of miR-144 and miR-34a
-
Shaghayegh Pishkari
,
Ameneh Koochaki
,
Javad Razaviyan
,
Mahdi Paryan
,
Mehrdad Hashemi
und
Samira Mohammadi-Yeganeh
Abstract
Objectives
The aim of the present study was to investigate the expression of AXL and mTOR genes and their targeting microRNAs (miRNAs) including miR-34a and miR-144 in Medullary Thyroid Carcinoma (MTC) cell line, TT, and determine the effect of these two miRNAs on their target genes to introduce new molecular markers or therapeutics.
Methods
The expression of miR-34a, miR-144, and their targets genes including AXL and mTOR was evaluated by quantitative Real-time PCR. Luciferase assay was performed to confirm the interaction between miRNAs and their target mRNAs. The expression level of AXL and mTOR was evaluated before and after miRNAs induction in TT cell line compared with Cos7 as control cells.
Results
The expression of AXL and mTOR were up-regulated significantly, while miR-34a and miR-144 were down-regulated in TT cell line compared to Cos7. After transduction, the overexpression of miR-34a and 144 caused down-regulation of both genes. Luciferase assay results showed that the mTOR is targeted by miR-34a and miR-144 and the intensity of luciferase decreased in the presence of miRNAs.
Conclusions
Based on the results of the present study and since AXL and mTOR genes play a critical role in variety of human cancers, suppression of these genes by their targeting miRNAs, especially miR-34a and miR-144, can be propose as a new strategy for MTC management. However, more studies are needed to approve the hypothesis.
Funding source: Shahid Beheshti University of Medical Sciences
Acknowledgments
The authors thank the Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences and also Pasteur Institute of Iran, Tehran, Iran for providing technical support.
-
Research funding: This project was funded by the Shahid Beheshti University of Medical Sciences, Tehran, Iran.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: The authors declare no conflict of interest.
-
Informed consent: Not applicable.
-
Ethical approval: Not applicable.
References
1. Cabanillas, ME, Dadu, R, Hu, MI, Lu, CH, Gunn, GB, Grubbs, EG, et al.. Thyroid gland malignancies. Hematol/Oncol Clin 2015;29:1123–43. https://doi.org/10.1016/j.hoc.2015.07.011.Suche in Google Scholar PubMed
2. Jung, KY, Kim, SM, Yoo, WS, Kim, BW, Lee, YS, Kim, KW, et al.. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence‐free survival of medullary thyroid cancer: a large‐scale retrospective analysis over 30 years. Clin Endocrinol 2016;84:587–97. https://doi.org/10.1111/cen.12852.Suche in Google Scholar PubMed
3. Celano, M, Rosignolo, F, Maggisano, V, Pecce, V, Lannone, M, Russo, D, et al.. MicroRNAs as biomarkers in thyroid carcinoma. Int J Genom 2017;2017. https://doi.org/10.1155/2017/6496570.Suche in Google Scholar PubMed PubMed Central
4. Avilla, E, Guarino, V, Visciano, C, Liotti, F, Svelto, M, Krishnamoorthy, GP, et al.. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Canc Res 2011;71:1792–804. https://doi.org/10.1158/0008-5472.can-10-2186.Suche in Google Scholar
5. Miller, MA, Oudin, MJ, Sullivan, RJ, Wang, SJ, Meyer, AS, Im, H, et al.. Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance. Canc Discov 2016;6:382–99. https://doi.org/10.1158/2159-8290.cd-15-0933.Suche in Google Scholar PubMed PubMed Central
6. Collina, F, La Sala, L, Liotti, F, Prevete, N, La Mantia, E, Chiofalo, MG, et al.. AXL is a novel predictive factor and therapeutic target for radioactive iodine refractory thyroid cancer. Cancers 2019;11:785. https://doi.org/10.3390/cancers11060785.Suche in Google Scholar PubMed PubMed Central
7. Grozinsky-Glasberg, S, Rubinfeld, H, Nordenberg, Y, Gorshtein, A, Praiss, M, Kendler, E, et al.. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol 2010;315:87–94. https://doi.org/10.1016/j.mce.2009.09.027.Suche in Google Scholar PubMed
8. Lyra, J, Vinagre, J, Batista, R, Pinto, V, Prazeres, H, Rodrigues, F, et al.. mTOR activation in medullary thyroid carcinoma with RAS mutation. Eur J Endocrinol 2014;171:633–40. https://doi.org/10.1530/eje-14-0389.Suche in Google Scholar
9. Elkabets, M, Pazarentzos, E, Juric, D, Sheng, Q, Pelossof, RA, Brook, S, et al.. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Canc Cell 2015;27:533–46. https://doi.org/10.1016/j.ccell.2015.03.010.Suche in Google Scholar PubMed PubMed Central
10. Schneider, T, De Wit, D, Links, T, van Erp, NP, van der Hoeven, JJM, Gelderblom, H, et al.. Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial. Int J Endocrinol 2015;2015. https://doi.org/10.1155/2015/348124.Suche in Google Scholar PubMed PubMed Central
11. Song, C-Q, Zhang, J-H, Shi, J-C, Cao, XQ, Song, CH, Hassan, A, et al.. Bioinformatic prediction of SNPs within miRNA binding sites of inflammatory genes associated with gastric cancer. Asian Pac J Cancer Prev 2014;15:937–43. https://doi.org/10.7314/apjcp.2014.15.2.937.Suche in Google Scholar PubMed
12. Canturk, KM, Ozdemir, M, Can, C, Öner, S, Emre, R, Aslan, H, et al.. Investigation of key miRNAs and target genes in bladder cancer using miRNA profiling and bioinformatic tools. Mol Biol Rep 2014;41:8127–35. https://doi.org/10.1007/s11033-014-3713-5.Suche in Google Scholar PubMed
13. Xi, Y, Edwards, JR, Ju, J. Investigation of miRNA biology by bioinformatic tools and impact of miRNAs in colorectal cancer—regulatory relationship of c-Myc and p53 with miRNAs. Canc Inf 2007;3. https://doi.org/10.1177/117693510700300011.Suche in Google Scholar
14. Nikiforova, MN, Tseng, GC, Steward, D, Diorio, D, Nikiforov, YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600–8. https://doi.org/10.1210/jc.2007-2696.Suche in Google Scholar PubMed PubMed Central
15. Pallante, P, Visone, R, Ferracin, M, Ferraro, A, Berlingieri, MT, Troncone, G, et al.. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Canc 2006;13:497–508. https://doi.org/10.1677/erc.1.01209.Suche in Google Scholar PubMed
16. Chu, Y-H, Lloyd, RV. Medullary thyroid carcinoma: recent advances including microRNA expression. Endocr Pathol 2016;27:312–24. https://doi.org/10.1007/s12022-016-9449-0.Suche in Google Scholar PubMed
17. Mudduluru, G, Ceppi, P, Kumarswamy, R, Scagliotti, GV, Papotti, M, Allgayer, H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011;30:2888. https://doi.org/10.1038/onc.2011.13.Suche in Google Scholar PubMed
18. Shabani, N, Razaviyan, J, Paryan, M, Tavangar, SM, Azizi, F, Mohammadi-Yeganeh, S, et al.. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. Hum Pathol 2018;79:212–21. https://doi.org/10.1016/j.humpath.2018.05.019.Suche in Google Scholar PubMed
19. Zabel, M, Grzeszkowak, J. Characterisation of thyroid medullary carcinoma TT cell line. Histol Histopathol 1997;12:283–9.Suche in Google Scholar
20. Levy, HC, Hulvey, D, Adamson-Small, L, Jn-Simon, N, Prima, V, Rivkees, S, et al.. Improved cell-specificity of adeno-associated viral vectors for medullary thyroid carcinoma using calcitonin gene regulatory elements. PloS One 2020;15:e0228005. https://doi.org/10.1371/journal.pone.0228005.Suche in Google Scholar PubMed PubMed Central
21. Yang, X, Liu, G, Li, W, Zang, L, Li, D, Wang, Q, et al.. Silencing of zinc finger protein 703 inhibits medullary thyroid carcinoma cell proliferation in vitro and in vivo. Oncol Lett 2020;19:943–51.10.3892/ol.2019.11153Suche in Google Scholar PubMed PubMed Central
22. Wang, H, Tang, J, Su, Z. YAP confers resistance to vandetanib in medullary thyroid cancer. Biochem Cell Biol 2020;98:443–8. https://doi.org/10.1139/bcb-2019-0354.Suche in Google Scholar PubMed
23. Giardino, E, Catalano, R, Mangili, F, Barbieri, AM, Treppiedi, D, Elli, FM, et al.. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion. Mol Cell Endocrinol 2020;111092. https://doi.org/10.1016/j.mce.2020.111092.Suche in Google Scholar PubMed
24. Karimkhanloo, H, Mohammadi-Yeganeh, S, Ahsani, Z, Paryan, M. Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma. Tumor Biol 2017;39. https://doi.org/10.1177/1010428317698361.Suche in Google Scholar PubMed
25. Jiang, M, Shi, X, Zhu, H, Wei, W, Li, J. Two GEO microRNA expression profile based high-throughput screen to identify microRNA-31-3p regulating growth of medullary thyroid carcinoma cell by targeting RASA2. Med Sci Mon Int Med J Exp Clin Res 2019;25:5170. https://doi.org/10.12659/msm.916815.Suche in Google Scholar PubMed PubMed Central
26. Rossing, M, Borup, R, Henao, R, Winther, O, Vikesaa, J, Niazi, O, et al.. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. J Mol Endocrinol 2012;48:11–23. https://doi.org/10.1530/jme-11-0039.Suche in Google Scholar
27. Santarpia, L, Calin, GA, Adam, L, Ye, L, Fusco, A, Giunti, S, et al.. A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Canc 2013;20:809–23. https://doi.org/10.1530/erc-13-0357.Suche in Google Scholar
28. Iwaya, T, Yokobori, T, Nishida, N, Kogo, R, Sudo, T, Tanaka, F, et al.. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis 2012;33:2391–7. https://doi.org/10.1093/carcin/bgs288.Suche in Google Scholar PubMed
29. Liu, J, Feng, L, Zhang, H, Zhang, J, Zhang, Y, Li, S, et al.. Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation. Canc Biol Ther 2018;19:484–96. https://doi.org/10.1080/15384047.2018.1433502.Suche in Google Scholar PubMed PubMed Central
30. Chen, P, Chen, F, Lei, J, Li, Q, Zhou, B. Activation of the miR-34a-mediated SIRT1/mTOR signalling pathway by urolithin a attenuates D-galactose-induced brain aging in mice. Neurotherapeutics 2019;16:1269–82. https://doi.org/10.1007/s13311-019-00753-0.Suche in Google Scholar PubMed PubMed Central
31. Cho, C-Y, Huang, J-S, Shiah, S-G, Chung, SY, Lay, J-D, Yang, Y-Y, et al.. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells. RNA 2016;22:303–15. https://doi.org/10.1261/rna.052571.115.Suche in Google Scholar PubMed PubMed Central
32. Liu, F, Zhang, J, Qin, L, Yang, Z, Xiong, J, Zhang, Y, et al.. Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation. Aging (Albany NY) 2018;10:3806. https://doi.org/10.18632/aging.101674.Suche in Google Scholar PubMed PubMed Central
33. Sun, J, Shi, R, Zhao, S, Li, X, Lu, SH, Bu, H, et al.. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. J Exp Clin Canc Res 2017;36:40. https://doi.org/10.1186/s13046-017-0504-6.Suche in Google Scholar PubMed PubMed Central
34. Liu, C, Su, C, Chen, Y, Li, G. MiR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8. Canc Cell Int 2018;18:54. https://doi.org/10.1186/s12935-018-0550-y.Suche in Google Scholar PubMed PubMed Central
35. Li, Y, Zeng, C, Hu, J, Pan, Y, Shan, Y, Liu, B, et al.. Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression. J Hematol Oncol 2018;11:89. https://doi.org/10.1186/s13045-018-0632-2.Suche in Google Scholar PubMed PubMed Central
36. Xiang, C, Cui, S-p, Ke, Y. MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR. J Huazhong Univ Sci Technol – Med Sci 2016;36:186–92. https://doi.org/10.1007/s11596-016-1564-0.Suche in Google Scholar PubMed
37. Badi, I, Mancinelli, L, Polizzotto, A, Ferri, D, Zeni, F, Burba, I, et al.. miR-34a promotes vascular smooth muscle cell calcification by downregulating SIRT1 (sirtuin 1) and Axl (AXL receptor tyrosine kinase). Arterioscler Thromb Vasc Biol 2018;38:2079–90. https://doi.org/10.1161/atvbaha.118.311298.Suche in Google Scholar PubMed
38. Yazdi, SH, Paryan, M, Mohammadi-Yeganeh, S. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer. Cell Mol Biol Lett 2018;23:51.10.1186/s11658-018-0116-ySuche in Google Scholar PubMed PubMed Central
39. Liao, H, Xiao, Y, Hu, Y, Xiao, Y, Yin, ZH, Liu, L, et al.. Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK/mTOR pathway in prostate cancer. Oncol Rep 2016;35:64–72. https://doi.org/10.3892/or.2015.4331.Suche in Google Scholar PubMed
40. Mian, C, Pennelli, G, Fassan, M, Balistreri, M, Barollo, S, Cavedon, E, et al.. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 2012;22:890–6. https://doi.org/10.1089/thy.2012.0045.Suche in Google Scholar PubMed PubMed Central
© 2021 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Original Articles
- Investigating the relationship between insulin resistance and adipose tissue in a randomized Tehrani population
- Antitumor effects of Auraptene in 4T1 tumor‐bearing Balb/c mice
- Voluntary exercise improves sperm parameters in high fat diet receiving rats through alteration in testicular oxidative stress, mir-34a/SIRT1/p53 and apoptosis
- Assessment of AXL and mTOR genes expression in medullary thyroid carcinoma (MTC) cell line in relation with over expression of miR-144 and miR-34a
- Is there a relation between serum methylarginine levels and infertility?
- Evaluation of Y chromosome microdeletions and chromosomal anomalies in infertile men
- Threshold values of antibodies to estrogen, progesteron and benzo [a] pyrene as a risk factor for the development of endometriosis
- Altered methylarginine levels after surgery in subjects with multinodular goiter
- Effects of eight weeks exercise training on serum levels of adropin in male volleyball players
- Urinary bisphenol A in women with polycystic ovary syndrome – a possible suppressive effect on steroidogenesis?
- Complementary role of p57kip2 immunostaining in diagnosing hydatidiform mole subtypes
- Short Communications
- Circulating Inhibitory Factor 1 levels in adult patients with Prader–Willi syndrome
- Determinants of serum adiponectin levels: a cross-sectional study
- Case Report
- Prophylactic gonadectomy in 46 XY females; why, where and when?
- Review Article
- Is the beta estradiol receptor receiving enough attention for its metabolic importance in postmenopause?
Artikel in diesem Heft
- Frontmatter
- Original Articles
- Investigating the relationship between insulin resistance and adipose tissue in a randomized Tehrani population
- Antitumor effects of Auraptene in 4T1 tumor‐bearing Balb/c mice
- Voluntary exercise improves sperm parameters in high fat diet receiving rats through alteration in testicular oxidative stress, mir-34a/SIRT1/p53 and apoptosis
- Assessment of AXL and mTOR genes expression in medullary thyroid carcinoma (MTC) cell line in relation with over expression of miR-144 and miR-34a
- Is there a relation between serum methylarginine levels and infertility?
- Evaluation of Y chromosome microdeletions and chromosomal anomalies in infertile men
- Threshold values of antibodies to estrogen, progesteron and benzo [a] pyrene as a risk factor for the development of endometriosis
- Altered methylarginine levels after surgery in subjects with multinodular goiter
- Effects of eight weeks exercise training on serum levels of adropin in male volleyball players
- Urinary bisphenol A in women with polycystic ovary syndrome – a possible suppressive effect on steroidogenesis?
- Complementary role of p57kip2 immunostaining in diagnosing hydatidiform mole subtypes
- Short Communications
- Circulating Inhibitory Factor 1 levels in adult patients with Prader–Willi syndrome
- Determinants of serum adiponectin levels: a cross-sectional study
- Case Report
- Prophylactic gonadectomy in 46 XY females; why, where and when?
- Review Article
- Is the beta estradiol receptor receiving enough attention for its metabolic importance in postmenopause?
